Table of Contents
|
|
|
|
Preface |
ix |
|
Abbreviations Used in this Manual |
x |
|
Generic Medications and Brand-Name
Equivalents |
xii |
I |
INTRODUCTION |
1 |
A |
Definition of Cancer |
1 |
B |
Treatment Modalities |
2 |
C |
The Drug Development Process |
4 |
D |
Ethical Issues Related to Cancer
Therapy |
11 |
E |
Legal Issues Related to Cancer Therapy |
12 |
II |
CANCER
THERAPY GOALS AND RESPONSE |
17 |
A |
Goals of Cancer Therapy |
17 |
B |
Factors Affecting Response to Treatment |
17 |
C |
Treatment Strategies |
18 |
D |
Measuring Response |
19 |
III |
PRINCIPLES
OF ANTINEOPLASTIC
THERAPY |
25 |
A |
Life Cycle of Cells |
25 |
B |
Chemotherapeutic Agents |
26 |
C |
Actions of the Immune System |
26 |
D |
Types of Immune Response |
26 |
E |
Cells of the Immune System |
28 |
F |
Tumor Escape Mechanisms |
29 |
G |
Principles of Biotherapy |
30 |
H |
Categories of Biotherapy |
30 |
I |
Principles of Radioimmunotherapy |
32 |
J |
Toxin-Conjugated Molecules |
33 |
K |
Therapeutic Uses for Biotherapeutic
Agents |
33 |
L |
Supportive Uses for Biotherapeutic
Agents |
33 |
M |
Biotherapeutic Strategies |
33 |
N |
Angiogenesis and Antiangiogenic
Agents |
34 |
IV |
FUNDAMENTALS
OF ADMINISTRATION |
73 |
A |
Safe Handling |
73 |
B |
Verification and Maintenance of Treatment
as Planned |
84 |
C |
Pretreatment |
93 |
D |
Treatment |
95 |
V |
IMMEDIATE
COMPLICATIONS OF CYTOTOXIC
THERAPY |
105 |
A |
Extravasation |
105 |
B |
Irritation |
110 |
C |
Flare Reaction |
111 |
D |
Acute Infusion Reactions |
111 |
E |
Patient and Family Education |
114 |
VI |
CARE
OF THE PATIENT RECEIVING CANCER THERAPY |
117 |
A |
Patient Education |
117 |
B |
Adherence to Therapy |
118 |
C |
Toxicity Management |
118 |
VII |
SIDE
EFFECTS OF CANCER THERAPY |
121 |
A |
Myelosuppression |
121 |
B |
GI and Mucosal Side Effects |
146 |
C |
Cutaneous Toxicity |
182 |
D |
Alopecia |
197 |
E |
Cardiovascular Toxicity |
200 |
F |
Pulmonary Toxicity |
231 |
G |
Hemorrhagic Cystitis |
255 |
H |
Hepatotoxicity |
259 |
I |
Nephrotoxicity |
266 |
J |
Neurotoxicity |
274 |
K |
Cancer Treatment-Related Cognitive
Changes |
284 |
L |
Ocular Toxicity |
300 |
M |
Pancreatitis |
310 |
N |
Fatigue |
311 |
O |
Alterations in Sexuality |
315 |
P |
Reproductive Alterations |
320 |
VIII |
POST-TREATMENT
CARE |
325 |
A |
General Principles |
325 |
B |
Types of Effects |
326 |
C |
Secondary Malignancies |
326 |
D |
Collaborative Management |
339 |
E |
Preventive Screening Recommendations |
340 |
F |
Patient and Family Education |
340 |
G |
Professional Education |
340 |
H |
Nursing Assessment |
340 |
IX |
NURSING
EDUCATION AND MANAGEMENT |
343 |
A |
The Clinical Practicum |
343 |
B |
Policy and Procedure |
344 |
C |
Issues in Antineoplastic
Administration |
344 |
D |
Documentation |
345 |
|
APPENDICES |
347 |
Appendix 1 |
Nursing Flow Sheet |
347 |
Appendix 2 |
Chemotherapy Flow Sheet |
351 |
Appendix 3 |
Safe Management of Chemotherapy in the
Home |
353 |
Appendix 4 |
Progression of Intravenous Extravasation |
355 |
Appendix 5 |
Clinical Practicum Evaluation: Part I |
356 |
Appendix 6 |
Clinical Practicum Evaluation: Part II |
357 |
Appendix 7 |
Oncology Nursing Society Position on
the Education of the RN Who Administers and Cares for the Individual
Receiving Chemotherapy and Biotherapy |
358 |
Appendix 8 |
Consent Document |
359 |
Appendix 9 |
Extravasation Flow Sheet |
360 |
|
Index |
361 |
|
|
|